Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 15/20 | 0.60 |
| ▸ | CDK8 | P49336 | 15/20 | 0.60 |
| ▸ | CDK19 | Q9BWU1 | 15/20 | 0.60 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.41 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.41 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7040357 | 1.00 | CCNC (0.60) | CCNCCDK8CDK19GPBAR1CDK9 | |
| SCHEMBL7035339 | 0.93 | CCNC (0.50) | CCNCCDK8CDK19GPBAR1ALOX5 | |
| SCHEMBL7038611 | 0.90 | CCNC (0.49) | CCNCCDK8CDK19GPBAR1ALOX5 | |
| SCHEMBL7039481 | 0.87 | CCNC (0.65) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL28845060 | 0.83 | CCNC (0.40) | CCNCCDK8CDK19GPBAR1ALOX5 | |
| SCHEMBL7242836 | 0.82 | CCNC (0.68) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7043844 | 0.82 | CCNC (0.64) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7036696 | 0.81 | CCNC (0.69) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7246947 | 0.81 | CCNC (0.68) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7242660 | 0.80 | CCNC (0.71) | CCNCCDK8CDK19CDK9MAP3K19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119950814-A | Cartilage organoid constructed based on DNA-silk fibroin hybrid hydrogel slow-release system and preparation method and application thereof | 上海大学 | 2025-05-09 | — | — | CN | claimed |
| CN-117679389-A | Active oxygen response drug release nano-particle with osteoarthritis cartilage surface crack targeting effect and preparation method thereof | 浙江大学绍兴研究院 | 2024-03-12 | — | — | CN | claimed |
| CN-115054579-B | Nanoparticle arthritis drug for active oxygen responsive gradient drug delivery and preparation method thereof | 浙江大学 | 2023-06-30 | — | — | CN | claimed |
| EP-4172319-A1 | PERIPHERAL BLOOD DERIVED SMALL PLURIPOTENT CELLS | Tithon Biotech, Inc. (US) | 2023-05-03 | — | — | EP | claimed |
| CN-115054579-A | Nanoparticle arthritis drug with active oxygen responsive gradient drug delivery and preparation method thereof | 浙江大学 | 2022-09-16 | — | — | CN | claimed |
| EP-3792262-B1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2026-04-15 | — | — | EP | disclosed |
| CN-119950814-B | Cartilage organoid constructed based on DNA-silk fibroin hybrid hydrogel slow-release system and preparation method and application thereof | 上海大学 | 2025-12-12 | — | — | CN | disclosed |
| US-20250333412-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2025-10-30 | — | — | US | disclosed |
| US-20250312378-A1 | COMPOSITION COMPRISING ANTI-FOLIC ACID AGENT FOR DIFFERENTIATION OF MESENCHYMAL STEM CELL INTO CARTILAGE | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2025-10-09 | — | — | US | disclosed |
| CN-119950814-A | Cartilage organoid constructed based on DNA-silk fibroin hybrid hydrogel slow-release system and preparation method and application thereof | 上海大学 | 2025-05-09 | — | — | CN | disclosed |
| CN-119950814-A | Cartilage organoid constructed based on DNA-silk fibroin hybrid hydrogel slow-release system and preparation method and application thereof | 上海大学 | 2025-05-09 | — | — | CN | disclosed |
| US-12275733-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2025-04-15 | — | — | US | disclosed |
| US-20230235288-A1 | PERIPHERAL BLOOD DERIVED SMALL PLURIPOTENT CELLS | TITHON BIOTECH, INC. | 2023-07-27 | — | — | US | disclosed |
| CN-115054579-B | Nanoparticle arthritis drug for active oxygen responsive gradient drug delivery and preparation method thereof | 浙江大学 | 2023-06-30 | — | — | CN | disclosed |
| EP-4172319-A1 | PERIPHERAL BLOOD DERIVED SMALL PLURIPOTENT CELLS | Tithon Biotech, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230107128-A1 | SCREENING SYSTEM FOR HUMAN-TRANSFORMED CARTILAGE CELL LINE-BASED CARTILAGE DISEASE TREATMENT AGENTS | LUGEN SCI CO., LTD. (KR) | 2023-04-06 | — | — | US | disclosed |
| WO-2023043262-A1 | COMPOSITION COMPRISING ANTI-FOLIC ACID AGENT FOR DIFFERENTIATION OF MESENCHYMAL STEM CELL INTO CARTILAGE | 이화여자대학교 산학협력단 | 2023-03-23 | — | — | WO | disclosed |
| WO-2022196613-A1 | METHOD FOR PRODUCING SCLEROTOME CELLS AND UTILIZATION OF SAID SCLEROTOME CELLS | 国立大学法人 長崎大学 | 2022-09-22 | — | — | WO | disclosed |
| CN-115054579-A | Nanoparticle arthritis drug with active oxygen responsive gradient drug delivery and preparation method thereof | 浙江大学 | 2022-09-16 | — | — | CN | disclosed |
| CN-110382496-B | Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders | 赛诺菲 | 2022-08-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275733-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | CCNC 147/4885CDK8 757/4885CDK19 594/4885 |
| US-20250333412-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | COL2A1, IDO1, COL1A1 | CCNC 146/4885CDK8 780/4885CDK19 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.